Members in the polypeptide N-acetylgalactosaminyltransferase (GALNT) family function as the initiating enzymes to catalyze mucin-type O-glycosylation of proteins, of which dysregulated expression can alter cancer cell behaviors such as de novo occurrence, proliferation, migration, metastasis and drug resistance. One of its members, GALNT14, is aberrantly expressed in multiple cancers and involved in a variety of biological functions. Moreover, the single nucleotide polymorphisms (SNPs) of

GALNT14

-rs9679162 has been shown to predict the therapeutic outcomes in patients with hepatocellular carcinoma as well as several other different types of gastrointestinal cancers.